Biomx Inc PHGE

Alternate Symbol(s): PHGE.U | PHGEW

Healthcare Biotechnology

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

NYSEAM:PHGE - Post by User

Biomx Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Mar 06, 2024 10:45am

42 Views

Post# 35918003

BiomX Agrees to Merge with Adaptive Phage Therapeutics and C

News; $PHGE BiomX Agrees to Merge with Adaptive Phage Therapeutics and Concurrent $50 M Financing2024-03-06 08:09:27 ET DENVER, Colo., Mar 06, 2024 ( 247marketnews.com )- BiomX Inc. (NYSE: PHGE ) stated, this morning, that it agreed to merge with Adaptive Phage Therapeutics, Inc. (“APT”), a privately-held, clinical-stage biotechnology company that’s based i...PHGE - BiomX Agrees to Merge with Adaptive Phage Therapeutics and Concurrent $50 M Financing

<< Previous

Bullboard Posts

Next >>

First Quantum hopes Panama’s new president will revive its copper mine